Increasing clinical pregnancy rates after IVF/ET. Can immunosuppression help?

Area of Science:

• Reproductive Medicine
• Immunology

Background:

• In vitro fertilization/embryo transfer (IVF-ET) success rates can be influenced by various factors.
• The role of immunosuppression in enhancing IVF-ET outcomes is an area of ongoing research.

Purpose of the Study:

• To evaluate the safety and efficacy of prednisone as an adjunct therapy to improve IVF-ET success.
• To determine if immunosuppression can positively impact implantation and pregnancy rates in IVF-ET patients.

Main Methods:

• A randomized, double-blind, placebo-controlled clinical trial was conducted.
• Seventy-five patients undergoing IVF-ET were randomized to receive either prednisone or a placebo.
• Patient demographics and preembryo transfer numbers were similar between groups.

Main Results:

• The prednisone group exhibited higher implantation rates (16% vs. 11%) and clinical pregnancy rates (43.5% vs. 32.3%) compared to the placebo group.
• These observed differences did not reach statistical significance.
• Ongoing pregnancy rates were similar between the prednisone (30.7%) and placebo (28.0%) groups.
• No adverse side effects were reported in either treatment group.

Conclusions:

• Prednisone as an adjunct to IVF-ET did not demonstrate statistically significant improvements in implantation or pregnancy rates.
• The treatment was found to be safe, with no reported side effects.
• Further research may be warranted to explore the potential role of immunosuppression in specific patient populations or with different protocols.